PrEP, or pre-exposure prophylaxis, is an HIV prevention method prescribed to HIV-negative adults and adolescents who are at high risk for getting HIV through sex or injection drug use. It allows those who don’t already have HIV to take a daily pill to reduce their risk of getting HIV if exposed to the virus. Studies have shown that PrEP reduces the risk of getting HIV from sex by about 99% when taken daily, and that it is highly effective for preventing HIV if it is used as prescribed. Among people who inject drugs, PrEP reduces the risk of getting HIV by at least 74% when taken daily. PrEP is much less effective when it is not taken consistently.
Currently, there are only two FDA-approved medications for PrEP:
The following websites provide general information about PrEP, including how it works, who and should take it and why, safety issues, cost and how to obtain it:
The following promotional and informational tools can provide context on how PReP has been presented and communicated to the public.
Rutgers is an equal access/equal opportunity institution. Individuals with disabilities are encouraged to direct suggestions, comments, or complaints concerning any accessibility issues with Rutgers websites to email@example.com or complete the Report Accessibility Barrier / Provide Feedback form.